Abivax has recovered from a dent in its share price after unveiling fresh safety data that appeared to ease investors’ concerns with its ulcerative colitis prospect.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Abivax has recovered from a dent in its share price after unveiling fresh safety data that appeared to ease investors’ concerns with its ulcerative colitis prospect.